AU2013251785B2 - Method for developing natural killer cells from stem cells - Google Patents

Method for developing natural killer cells from stem cells Download PDF

Info

Publication number
AU2013251785B2
AU2013251785B2 AU2013251785A AU2013251785A AU2013251785B2 AU 2013251785 B2 AU2013251785 B2 AU 2013251785B2 AU 2013251785 A AU2013251785 A AU 2013251785A AU 2013251785 A AU2013251785 A AU 2013251785A AU 2013251785 B2 AU2013251785 B2 AU 2013251785B2
Authority
AU
Australia
Prior art keywords
cells
cell
pct
culturing
rule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013251785A
Other languages
English (en)
Other versions
AU2013251785A1 (en
Inventor
Dan S. Kaufman
David A. Knorr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2013251785A1 publication Critical patent/AU2013251785A1/en
Application granted granted Critical
Publication of AU2013251785B2 publication Critical patent/AU2013251785B2/en
Priority to AU2018206749A priority Critical patent/AU2018206749A1/en
Priority to AU2020264375A priority patent/AU2020264375B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1171—Haematopoietic stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2013251785A 2012-04-24 2013-04-23 Method for developing natural killer cells from stem cells Ceased AU2013251785B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018206749A AU2018206749A1 (en) 2012-04-24 2018-07-18 Method for developing natural killer cells from stem cells
AU2020264375A AU2020264375B2 (en) 2012-04-24 2020-11-06 Method for developing natural killer cells from stem cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261637592P 2012-04-24 2012-04-24
US61/637,592 2012-04-24
PCT/US2013/037782 WO2013163171A1 (en) 2012-04-24 2013-04-23 Method for developing natural killer cells from stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018206749A Division AU2018206749A1 (en) 2012-04-24 2018-07-18 Method for developing natural killer cells from stem cells

Publications (2)

Publication Number Publication Date
AU2013251785A1 AU2013251785A1 (en) 2014-09-18
AU2013251785B2 true AU2013251785B2 (en) 2018-05-10

Family

ID=48289670

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013251785A Ceased AU2013251785B2 (en) 2012-04-24 2013-04-23 Method for developing natural killer cells from stem cells
AU2018206749A Abandoned AU2018206749A1 (en) 2012-04-24 2018-07-18 Method for developing natural killer cells from stem cells
AU2020264375A Ceased AU2020264375B2 (en) 2012-04-24 2020-11-06 Method for developing natural killer cells from stem cells

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018206749A Abandoned AU2018206749A1 (en) 2012-04-24 2018-07-18 Method for developing natural killer cells from stem cells
AU2020264375A Ceased AU2020264375B2 (en) 2012-04-24 2020-11-06 Method for developing natural killer cells from stem cells

Country Status (5)

Country Link
US (1) US9260696B2 (https=)
EP (2) EP2841563B1 (https=)
JP (3) JP6339998B2 (https=)
AU (3) AU2013251785B2 (https=)
WO (1) WO2013163171A1 (https=)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2841563B1 (en) * 2012-04-24 2019-06-12 Dan S. Kaufman Method for developing natural killer cells from stem cells
AU2014248119B2 (en) * 2013-04-03 2019-06-20 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
AU2016211671B2 (en) 2015-01-26 2022-05-26 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US10836997B2 (en) * 2015-03-09 2020-11-17 Keio University Method for differentiating pluripotent stem cells into desired cell type
WO2016187820A1 (zh) * 2015-05-26 2016-12-01 中国科学院广州生物医药与健康研究院 一种人原代细胞培养基及其应用
PL412787A1 (pl) * 2015-06-22 2017-01-02 Magdalena Król Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
AU2016299166B2 (en) * 2015-07-24 2022-03-31 Innate Pharma Methods for detecting tissue infiltrating NK cells
KR102675213B1 (ko) * 2015-09-08 2024-06-13 스미토모 파마 가부시키가이샤 망막 색소 표피 세포의 제조 방법
JP6928604B2 (ja) 2015-11-04 2021-09-01 フェイト セラピューティクス，インコーポレイテッド 万能性細胞のゲノム改変
CA3003152A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CN105296428A (zh) * 2015-12-03 2016-02-03 广州医科大学附属第三医院 一种提高诱导多能干细胞的体外分化造血效率的方法
ES2952064T3 (es) 2015-12-16 2023-10-26 Walter & Eliza Hall Inst Medical Res Inhibición de la proteína SH2 inducida por citocinas en células NK
JP7039473B2 (ja) * 2016-07-29 2022-03-22 ダイキン工業株式会社 分化細胞の製造方法、及びその製造方法のために使用する培養バッグ
US20190194621A1 (en) * 2016-09-08 2019-06-27 Kyowa Hakko Bio Co., Ltd. Medium for culturing stem cells, method for culturing stem cells, growth promoter for stem cells, and cell composition and method for producing same
WO2018147801A1 (en) * 2017-02-07 2018-08-16 Agency For Science, Technology And Research Methods and kits for generating mimetic innate immune cells from pluripotent stem cells
WO2018160673A1 (en) 2017-02-28 2018-09-07 University Of Central Florida Research Foundation, Inc. Pm21 particles to improve bone marrow homing of nk cells
EP3594322A4 (en) 2017-03-08 2021-01-27 Sumitomo Dainippon Pharma Co., Ltd. METHOD FOR PRODUCING RETINAPIGMENT EPITHELIAL CELLS
CN110997904B (zh) * 2017-03-21 2024-11-26 法国血液机构 改进造血移植物的方法
KR102167548B1 (ko) * 2017-09-21 2020-10-19 한국생명공학연구원 자연살해세포의 제조방법 및 그의 용도
JP7433230B2 (ja) * 2017-12-08 2024-02-19 ジュノー セラピューティクス インコーポレイテッド 細胞を培養するための無血清培地配合物およびその使用の方法
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
PT3755347T (pt) * 2018-02-21 2025-07-25 Univ Texas Células de apresentação de antigénio universais e utilizações destas
CN113474450A (zh) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物
CA3109804A1 (en) 2018-08-16 2020-02-20 The Regents Of The University Of California Chemically and photochemically initiated cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof
PT3843757T (pt) 2018-08-27 2024-07-08 Affimed Gmbh Células nk criopreservadas pré-carregadas com uma construção de anticorpo
US12497593B2 (en) 2018-09-07 2025-12-16 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
US20220119767A1 (en) * 2019-03-01 2022-04-21 The Regents Of The University Of California Natural killer cell induced cellular vesicles for cancer therapy
WO2020197318A1 (ko) * 2019-03-28 2020-10-01 한국생명공학연구원 Car 유전자가 도입된 nk 세포의 제조방법 및 그의 용도
RU2731293C1 (ru) 2019-04-12 2020-09-01 Игорь Петрович Белецкий Способ получения генно-модифицированных линий клеток натуральных киллеров с нокаутированным геном PD-1 и повышенной экспрессией белков семейства Фактора Некроза Опухолей для иммунотерапии онкологических заболеваний
WO2020220016A1 (en) * 2019-04-26 2020-10-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells comprising ligands for nkg2d for expanding immune cells for immunotherapy
CN114746543A (zh) 2019-11-13 2022-07-12 延世大学校产学协力团 分离纯培养血管内皮细胞的方法、维持血管内皮细胞特性的培养基和包括其的培养方法
CN111235105B (zh) * 2020-03-06 2021-08-10 安徽中盛溯源生物科技有限公司 一种从人多能干细胞分化为自然杀伤细胞的方法及应用
JP2023517220A (ja) * 2020-03-11 2023-04-24 リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル 微生物感染症の治療のためのｎｋ細胞およびそれらの使用
US11547726B2 (en) 2020-03-26 2023-01-10 Honed Life Sciences, Llc Enhancement of production of NK cells from stem cells
WO2021256522A1 (ja) 2020-06-17 2021-12-23 国立大学法人京都大学 キメラ抗原受容体発現免疫担当細胞
EP4189068A4 (en) * 2020-07-27 2024-08-28 Stemcell Technologies Canada Inc. SYSTEMS AND METHODS FOR DIFFERENTIATION OF HEMATOPOETIC CELLS
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
CN112608895B (zh) * 2020-12-18 2024-02-27 深圳市济因生物科技有限公司 一种人多能干细胞分化的自然杀伤细胞及其制备方法与应用
WO2022144632A1 (en) * 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
EP4326852A4 (en) * 2021-04-22 2025-04-23 Artec Biotech, Inc. Method for producing hematopoietic cells from stem cells using vascular organoids
WO2022269393A1 (en) 2021-06-23 2022-12-29 Crispr Therapeutics Ag Engineered cells with improved protection from natural killer cell killing
CN115261318B (zh) * 2021-09-29 2024-05-28 苏州艾凯利元生物科技有限公司 产生自然杀伤细胞的方法
US20250000974A1 (en) * 2021-10-27 2025-01-02 The Regents Of The University Of California Combination of human natural killer cells and macrophages for cancer therapy
CN113957048A (zh) * 2021-10-29 2022-01-21 深圳市默赛尔生物医学科技发展有限公司 一种利用脐带血单个核细胞生产自然杀伤细胞的方法
EP4448729A1 (en) 2021-12-17 2024-10-23 Umoja Biopharma, Inc. Cytotoxic innate lymphoid cell and uses thereof
US20250122474A1 (en) * 2022-01-31 2025-04-17 Healios K.K. Production method for natural killer cells
CN114507641B (zh) * 2022-04-20 2022-07-12 山东兴瑞生物科技有限公司 一种由人胚胎干细胞诱导分化为nk细胞的方法
WO2023233342A2 (en) 2022-06-01 2023-12-07 Crispr Therapeutics Ag Gene-edited natural killer cells
US20250354118A1 (en) * 2022-06-09 2025-11-20 Umoja Biopharma, Inc. Compositions and methods for nk cell differentiation
CN115058387B (zh) * 2022-06-11 2023-12-01 重庆医科大学 一种人胚胎干细胞与前列腺癌细胞共培养制备抗前列腺癌药物的方法
CA3263301A1 (en) * 2022-07-27 2024-02-01 Umoja Biopharma, Inc. Differentiation of stem cells in suspension culture
WO2024101863A1 (ko) * 2022-11-07 2024-05-16 마루테라퓨틱스 주식회사 줄기세포 기원 및 발현 마커에 따른 nk 세포 분화 효율 증진 방법
WO2024101862A1 (ko) * 2022-11-07 2024-05-16 마루테라퓨틱스 주식회사 Nk 세포의 분화 효율 및 기능성 증가를 위한 배양 방법
WO2024101919A1 (ko) * 2022-11-10 2024-05-16 의료법인 성광의료재단 전분화능 줄기세포에서 자연살해세포로의 분화 유도용 배지 조성물 및 이를 이용한 분화 방법
TW202506996A (zh) * 2023-04-27 2025-02-16 日商武田藥品工業股份有限公司 擴增ｃｄ５６＋／ｃｄ３－細胞之方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3065499D1 (en) 1979-04-11 1983-12-15 Mitsui Petrochemical Ind Process for producing spherical carrier particles for olefin polymerisation catalyst, catalyst comprising such carrier particles, and use of such catalyst in olefin polymerisation
EP0187371B1 (en) 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
JP3926842B2 (ja) 1995-03-08 2007-06-06 ザ・スクリプス・リサーチ・インステイチユート 抗原提示系およびｔ−細胞の活性化方法
ATE347588T1 (de) 1996-05-23 2006-12-15 Scripps Research Inst Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten
CA2277278A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
US6790662B1 (en) 1999-03-12 2004-09-14 Ortho-Mcneil Pharmaceutical, Inc. Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides
ES2295009T3 (es) 1999-03-25 2008-04-16 Mitsubishi Tanabe Pharma Corporation Inhibidores de rho quinasa para la profilaxis y el tratamiento de neumonia intersticial y fibrosis pulmonar.
AU5250400A (en) 1999-06-18 2001-01-09 Mitsubishi Pharma Corporation Osteogenesis promoters
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
US6664266B2 (en) 2002-03-14 2003-12-16 Children's Medical Center Corporation Axon regeneration with PKC inhibitiors
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
AU2003234185C1 (en) 2002-04-22 2009-11-19 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase C
CN101052712A (zh) 2004-09-08 2007-10-10 威斯康星校友研究基金会 培养人胚胎干细胞
ES2579762T3 (es) 2006-03-01 2016-08-16 Janssen Pharmaceutica N.V. Tratamiento del cáncer combinando agente linfo - reductor con CLTs y citoquinas
CA2665568C (en) 2006-10-04 2018-01-09 Janssen Pharmaceutica, N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
US8513012B2 (en) 2008-05-02 2013-08-20 Cellular Dynamics International, Inc. Method for production of mast cells from stem cells
KR101720961B1 (ko) 2009-02-27 2017-03-29 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 다능성 세포의 분화
CA3095576A1 (en) * 2009-12-04 2011-06-09 Astellas Institute For Regenerative Medicine Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
EP2841563B1 (en) * 2012-04-24 2019-06-12 Dan S. Kaufman Method for developing natural killer cells from stem cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KNORR DAVID A ET AL, "Differentiation of Human Natural Killer Cells From Pluripotent Stem Cells In a Feeder Free System Amenable to Clinical Translation", BLOOD, 2010, vol. 116, no. 21, page 53, Abstract 107 *

Also Published As

Publication number Publication date
JP2015519890A (ja) 2015-07-16
AU2020264375B2 (en) 2023-05-25
US20130287751A1 (en) 2013-10-31
AU2020264375A1 (en) 2020-12-03
AU2013251785A1 (en) 2014-09-18
JP6339998B2 (ja) 2018-06-06
EP2841563A1 (en) 2015-03-04
JP2017158590A (ja) 2017-09-14
JP2019122415A (ja) 2019-07-25
EP2841563B1 (en) 2019-06-12
WO2013163171A1 (en) 2013-10-31
US9260696B2 (en) 2016-02-16
AU2018206749A1 (en) 2018-08-09
JP6529541B2 (ja) 2019-06-12
EP3567102A1 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
AU2020264375B2 (en) Method for developing natural killer cells from stem cells
JP7138134B2 (ja) 血管コロニー形成細胞および非生着血管細胞
JP7343984B2 (ja) ヒト胚性幹細胞由来血管芽細胞からナチュラルキラー細胞および樹状細胞を生成する方法
US9988602B2 (en) Methods for producing enucleated erythroid cells derived from pluripotent stem cells
US20050221482A1 (en) Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof
HK40017506A (en) Method for developing natural killer cells from stem cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired